The purinergic receptor P2X7 and the NLRP3 inflammasome are druggable host factors required for SARS-CoV-2 infection
Abstract Purinergic receptors and NOD-like receptor protein 3 (NLRP3) inflammasome regulate inflammation and viral infection, but their effects on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection remain poorly understood. Here, we report that the purinergic receptor P2X7 and NLRP3 inflammasome are cellular host factors required for SARS-CoV-2 infection. Lung autopsies from patients with severe coronavirus disease 2019 (COVID-19) reveal that NLRP3 expression is increased in host cellular targets of SARS-CoV-2 including alveolar macrophages, type II pneumocytes and syncytia arising from the fusion of infected macrophages, thus suggesting a potential role of NLRP3 and associated signaling pathways to both inflammation and viral replication. In vitro studies demonstrate that NLRP3-dependent inflammasome activation is detected upon macrophage abortive infection. More importantly, a weak activation of NLRP3 inflammasome is also detected during the early steps of SARS-CoV-2 infection of epithelial cells and promotes the viral replication in these cells. Interestingly, the purinergic receptor P2X7, which is known to control NLRP3 inflammasome activation, also favors the replication of D614G and alpha SARS-CoV-2 variants. Altogether, our results reveal an unexpected relationship between the purinergic receptor P2X7, the NLRP3 inflammasome and the permissiveness to SARS-CoV-2 infection that offers novel opportunities for COVID-19 treatment..
| Medienart: |
|
|---|
Preprint| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
bioRxiv.org - (2024) vom: 23. Apr. Zur Gesamtaufnahme - year:2024 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Lécuyer, Déborah [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| doi: |
10.1101/2023.04.05.531513 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
XBI039177890 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | XBI039177890 | ||
| 003 | DE-627 | ||
| 005 | 20240425104734.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230406s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1101/2023.04.05.531513 |2 doi | |
| 035 | |a (DE-627)XBI039177890 | ||
| 035 | |a (biorXiv)10.1101/2023.04.05.531513 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Lécuyer, Déborah |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a The purinergic receptor P2X7 and the NLRP3 inflammasome are druggable host factors required for SARS-CoV-2 infection |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Abstract Purinergic receptors and NOD-like receptor protein 3 (NLRP3) inflammasome regulate inflammation and viral infection, but their effects on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection remain poorly understood. Here, we report that the purinergic receptor P2X7 and NLRP3 inflammasome are cellular host factors required for SARS-CoV-2 infection. Lung autopsies from patients with severe coronavirus disease 2019 (COVID-19) reveal that NLRP3 expression is increased in host cellular targets of SARS-CoV-2 including alveolar macrophages, type II pneumocytes and syncytia arising from the fusion of infected macrophages, thus suggesting a potential role of NLRP3 and associated signaling pathways to both inflammation and viral replication. In vitro studies demonstrate that NLRP3-dependent inflammasome activation is detected upon macrophage abortive infection. More importantly, a weak activation of NLRP3 inflammasome is also detected during the early steps of SARS-CoV-2 infection of epithelial cells and promotes the viral replication in these cells. Interestingly, the purinergic receptor P2X7, which is known to control NLRP3 inflammasome activation, also favors the replication of D614G and alpha SARS-CoV-2 variants. Altogether, our results reveal an unexpected relationship between the purinergic receptor P2X7, the NLRP3 inflammasome and the permissiveness to SARS-CoV-2 infection that offers novel opportunities for COVID-19 treatment. | ||
| 650 | 4 | |a Biology |7 (dpeaa)DE-84 | |
| 650 | 4 | |a 570 |7 (dpeaa)DE-84 | |
| 700 | 1 | |a Nardacci, Roberta |e verfasserin |4 aut | |
| 700 | 1 | |a Tannous, Désirée |e verfasserin |4 aut | |
| 700 | 1 | |a Gutierrez-Mateyron, Emie |e verfasserin |4 aut | |
| 700 | 1 | |a Deva-Nathan, Aurélia |e verfasserin |4 aut | |
| 700 | 1 | |a Subra, Frédéric |e verfasserin |4 aut | |
| 700 | 1 | |a Primio, Cristina Di |e verfasserin |4 aut | |
| 700 | 1 | |a Quaranta, Paola |e verfasserin |4 aut | |
| 700 | 1 | |a Petit, Vanessa |e verfasserin |4 aut | |
| 700 | 1 | |a Richetta, Clémence |e verfasserin |4 aut | |
| 700 | 1 | |a Mostefa-Kara, Ali |e verfasserin |4 aut | |
| 700 | 1 | |a Nonno, Franca Del |e verfasserin |4 aut | |
| 700 | 1 | |a Falasca, Laura |e verfasserin |4 aut | |
| 700 | 1 | |a Marlin, Romain |e verfasserin |4 aut | |
| 700 | 1 | |a Maisonnasse, Pauline |e verfasserin |4 aut | |
| 700 | 1 | |a Delahousse, Julia |e verfasserin |4 aut | |
| 700 | 1 | |a Pascaud, Juliette |e verfasserin |4 aut | |
| 700 | 1 | |a Deprez, Eric |e verfasserin |4 aut | |
| 700 | 1 | |a Naigeon, Marie |e verfasserin |4 aut | |
| 700 | 1 | |a Chaput, Nathalie |e verfasserin |4 aut | |
| 700 | 1 | |a Paci, Angelo |e verfasserin |4 aut | |
| 700 | 1 | |a Saada, Véronique |e verfasserin |4 aut | |
| 700 | 1 | |a Ghez, David |e verfasserin |4 aut | |
| 700 | 1 | |a Mariette, Xavier |e verfasserin |4 aut | |
| 700 | 1 | |a Costa, Mario |e verfasserin |4 aut | |
| 700 | 1 | |a Pistello, Mauro |e verfasserin |4 aut | |
| 700 | 1 | |a Allouch, Awatef |e verfasserin |4 aut | |
| 700 | 1 | |a Delelis, Olivier |e verfasserin |4 aut | |
| 700 | 1 | |a Piacentini, Mauro |e verfasserin |4 aut | |
| 700 | 1 | |a Le Grand, Roger |e verfasserin |4 aut | |
| 700 | 1 | |a Perfettini, Jean-Luc |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t bioRxiv.org |g (2024) vom: 23. Apr. |
| 773 | 1 | 8 | |g year:2024 |g day:23 |g month:04 |
| 856 | 4 | 0 | |u https://doi.org/10.3389/fimmu.2023.1270081 |x 0 |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1101/2023.04.05.531513 |x 0 |z kostenfrei |3 Volltext |
| 912 | |a GBV_XBI | ||
| 951 | |a AR | ||
| 952 | |j 2024 |b 23 |c 04 | ||